Year All202620252024 August 5, 2026 Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference Read More August 4, 2026 Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Read More July 30, 2026 Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing Read More July 28, 2026 Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026 Read More June 30, 2026 Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors Read More June 29, 2026 Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations Read More June 22, 2026 FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations Read More June 3, 2026 Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations Read More June 2, 2026 Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 Read More May 27, 2026 Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043 Read More
August 5, 2026 Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference Read More
August 4, 2026 Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Read More
July 30, 2026 Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing Read More
July 28, 2026 Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026 Read More
June 30, 2026 Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors Read More
June 29, 2026 Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations Read More
June 22, 2026 FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations Read More
June 3, 2026 Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations Read More
June 2, 2026 Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 Read More
May 27, 2026 Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043 Read More
